Literature DB >> 12191972

Evidence for the existence of two distinct functions for the inducible NO synthase in the rat kidney: effect of aminoguanidine in rats with 5/6 ablation.

Clarice Kazue Fujihara1, Ana Lúcia Mattar, José Mauro Vieira, Denise Maria Avancini Costa Malheiros, Irene de Lourdes Noronha, Anderson Ricardo Roman Gonçalves, Gilberto De Nucci, Roberto Zatz.   

Abstract

The functional role of the NO synthase (NOS) isoforms in the normal or diseased kidney is uncertain. This study examined the renal expression of the endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) isoforms by both immunohistochemistry and Western blot analyses in sham-operated rats (S) and in rats subjected to 5/6 nephrectomy (Nx). Primary antibodies from two different sources were used to detect iNOS. Additional S and Nx rats were chronically treated with aminoguanidine (AG), a selective iNOS inhibitor. All three isoforms were clearly expressed in S kidney. Their renal abundance, evaluated by Western blot analysis, fell in Nx rats. With the use of anti-iNOS antibodies from two distinct sources, the immunohistochemical analysis showed the presence of what appeared to be two distinct iNOS fractions: a "tubular" fraction, present in S and with decreased intensity in Nx; and an "interstitial" fraction, observed only in inflamed areas of Nx rats. AG treatment greatly attenuated renal injury in Nx rats by a direct antiinflammatory effect, likely related to iNOS inhibition, rather than to amelioration of renal hemodynamics or to reduced protein glycation. These observations suggest that: (1) the functional role of the renal iNOS isoform may vary dramatically under different physiologic conditions; (2) caution should be taken in the interpretation of immunohistochemical iNOS data, because antibodies from different sources may detect different iNOS fractions; and (3) AG treatment may become useful in the treatment of human progressive nephropathies, even those not associated with diabetes or aging.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191972     DOI: 10.1097/01.asn.0000027354.12330.f4

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

2.  Expression and cellular localization of inducible nitric oxide synthase in lipopolysaccharide-treated rat kidneys.

Authors:  Jae-Youn Choi; Sun-Ah Nam; Dong-Chan Jin; Jin Kim; Jung-Ho Cha
Journal:  J Histochem Cytochem       Date:  2012-01-19       Impact factor: 2.479

3.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase.

Authors:  Aaron Erdely; Laszlo Wagner; Veronica Muller; Attila Szabo; Chris Baylis
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

4.  Effects of N-hexacosanol on nitric oxide synthase system in diabetic rat nephropathy.

Authors:  Shinichi Okada; Motoaki Saito; Emi Kazuyama; Takuya Hanada; Yasuo Kawaba; Atsushi Hayashi; Keisuke Satoh; Susumu Kanzaki
Journal:  Mol Cell Biochem       Date:  2008-06-05       Impact factor: 3.396

5.  Antioxidant diet and sex interact to regulate NOS isoform expression and glomerular mesangium proliferation in Zucker diabetic rat kidney.

Authors:  Yuriy Slyvka; Ramiro Malgor; Sharon R Inman; Julia Ding; Victor Heh; Felicia V Nowak
Journal:  Acta Histochem       Date:  2016-01-18       Impact factor: 2.479

6.  Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats.

Authors:  Daisuke Ito; Pengyu Cao; Takaaki Kakihana; Emiko Sato; Chihiro Suda; Yoshikazu Muroya; Yoshiko Ogawa; Gaizun Hu; Tadashi Ishii; Osamu Ito; Masahiro Kohzuki; Hideyasu Kiyomoto
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.